Understanding mismatch repair IHC as a binary read — and how protein pairing patterns point toward the underlying gene defect.
Every time a cell divides, it must copy its entire genome — roughly 3 billion base pairs. Errors are inevitable. The mismatch repair systemA system of proteins that detect and fix errors introduced during DNA replication. is the cell’s proofreading mechanism: a group of proteins that scan newly replicated DNA, find mistakes, and fix them before they become permanent mutations.
The four proteins most clinically relevant to this process are MLH1, MSH2, MSH6, and PMS2The four MMR proteins tested by IHC. Each is the product of a specific gene in the MMR pathway.. They don’t work alone — they operate in pairs called heterodimersA pair of two different proteins that work together as a functional unit. MLH1 pairs with PMS2; MSH2 pairs with MSH6.: MLH1 bonds with PMS2, and MSH2 bonds with MSH6. These pairs are interdependent: if one partner is lost, the other becomes unstable and is also lost. This pairing relationship is one of the most important things a pathologist looks for when reading an MMR IHC panel, because it narrows down which gene is actually defective.
When the MMR system breaks down — either through an inherited gene mutation or an acquired one — replication errors accumulate unchecked. This leads to a pattern called microsatellite instability (MSI)A pattern of DNA replication errors that accumulates when the MMR system is not functioning — a hallmark of dMMR tumors., a hallmark of MMR-deficient tumors. MMR deficiency is found in approximately 15% of colorectal cancers and is also common in endometrial, gastric, and other cancer types.
Unlike p53 — which uses a three-tier classification — MMR protein IHC is read as a simple binary: proficient (pMMR)All four MMR proteins show intact nuclear staining — the repair system is functioning normally. or deficient (dMMR)One or more MMR proteins show complete loss of nuclear staining — the repair system has broken down..
Intact (proficient / pMMR) — normal, strong nuclear staining is present in tumor cells for all four proteins. This confirms the MMR system is functioning. A tumor is only classified as MMR-proficient when all four proteins show intact staining — if even one is lost, the tumor is deficient.
Deficient (lost / dMMR) — complete absence of nuclear staining in tumor cells for one or more proteins, despite intact staining in surrounding normal tissue (which confirms the test itself worked). Loss of one protein almost always pulls its heterodimer partner down with it.
ⓘ Schematic cell-field illustration showing nuclear staining patterns — not derived from actual IHC slide images.
Look for: strong nuclear staining present in tumor cells across all four proteins.
MMR IHC status has direct, immediate impact on patient care in two areas.
Lynch syndromeA hereditary condition caused by a germline mutation in one of the four MMR genes, significantly increasing lifetime cancer risk. is an inherited condition caused by a germline mutation in one of the four MMR genes. It is responsible for a notable proportion of colorectal cancers and significantly raises lifetime risk of endometrial, gastric, urinary tract, and other cancers. Identifying dMMR through IHC is often the first step in flagging a patient for Lynch syndrome evaluation — particularly when the IHC profile shows isolated PMS2 or MSH2/MSH6 loss, patterns less commonly caused by sporadic methylation and more likely to reflect a true germline mutation.
MMR deficiency (dMMR) / high microsatellite instability (MSI-H)A pattern of DNA replication errors that accumulates when the MMR system is not functioning — a hallmark of dMMR tumors. is a key biomarker used to determine eligibility for immune checkpoint inhibitor therapy — a class of cancer treatment that works by lifting the brakes on the immune system’s ability to attack tumors. The FDA has approved checkpoint inhibitors specifically for dMMR/MSI-H tumors across multiple cancer types regardless of where in the body the tumor originated, making accurate MMR IHC interpretation directly tied to whether a patient receives this treatment.
PCI-AI’s QuadControl™ panel includes cell lines for MLH1, MSH2, MSH6, and PMS2 — providing a characterized reference standard for MMR antibody optimization across the full four-protein panel.
View QuadControl™ →